Leo Pharma's eczema drug for adolescents meets phase III trial targets

The drug Adtralza, which is developed by Leo Pharma, has reached both its primary and secondary endpoints after a 16-week phase III trial testing the eczema treatment in patients with moderate-to-severe atopic dermatitis.

Photo: Leo Pharma / PR

At the 2021 Fall Clinical Dermatology Conference, held virtually and from Las Vegas, pharmaceutical company Leo Pharma presented data from a new trial of its antibody treatment tralokinumab, sold under the brand name Adtralza, which is approved in the EU, the UK and Canada as a treatment for adults with moderate-to-severe atopic dermatitis.

The new results come from the phase III trial Ecztra 6, which has investigated the treatment in the younger segment of patients aged 12 to 17. The participants have received Adtralza over 16 weeks in one of two dosages, or a placebo substance.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs